Meeting News Coverage

Triple-drug combo plus telaprevir did not worsen quality of life in patients with HCV

Researchers for the ADVANCE trial have found that the addition of telaprevir to therapy for patients with genotype 1 chronic hepatitis C did not further impair health-related quality of life.

For the trial, patients were randomly assigned to 12 weeks of telaprevir (Incivek, Vertex Pharmaceuticals) with 24 or 48 weeks of peginterferon alfa-2a and ribavirin, or peginterferon alfa-21 and ribavirin alone. More patients in the telaprevir arm achieved sustained virologic response. For the current analysis, researchers set out to determine whether telaprevir affected health-related quality of life.

“Although impairment of [quality of life] is expected with two or three drug regimens for hepatitis C, it was encouraging to see that addition of the third drug did not substantially impact [quality of life],” Zobair Younossi, MD, vice president of research and chairman of the department of medicine at Inova Health System in Falls Church, Va., said in a press release. “For patients with HCV genotype 1, the three-drug regimen with telaprevir not only improves sustained virologic response, but also does not seem to substantially worsen [quality of life].” 

Zobair Younossi
Zobair Younossi

Younossi and colleagues administered the EQ-5D questionnaire of quality of life to 722 patients enrolled in the ADVANCE study at baseline and at weeks 4, 12, 24, 36, 48 and 72. Across all treatment arms, quality-of-life scores worsened during the first 12 weeks, but they returned to baseline by week 72.

In multivariate analyses, after adjusting for EQ-5D baseline scores, age, sex, race, advanced liver disease, comorbidities and adverse events, sustained virologic response was associated with improved EQ-5D index scores at week 72.

References:

  • Younossi ZM. #SA1048. Presented at: Digestive Disease Week 2012 Annual Meeting; May 29-22: San Diego.

Disclosures:

  • The study was funded by Vertex Pharmaceuticals.

Researchers for the ADVANCE trial have found that the addition of telaprevir to therapy for patients with genotype 1 chronic hepatitis C did not further impair health-related quality of life.

For the trial, patients were randomly assigned to 12 weeks of telaprevir (Incivek, Vertex Pharmaceuticals) with 24 or 48 weeks of peginterferon alfa-2a and ribavirin, or peginterferon alfa-21 and ribavirin alone. More patients in the telaprevir arm achieved sustained virologic response. For the current analysis, researchers set out to determine whether telaprevir affected health-related quality of life.

“Although impairment of [quality of life] is expected with two or three drug regimens for hepatitis C, it was encouraging to see that addition of the third drug did not substantially impact [quality of life],” Zobair Younossi, MD, vice president of research and chairman of the department of medicine at Inova Health System in Falls Church, Va., said in a press release. “For patients with HCV genotype 1, the three-drug regimen with telaprevir not only improves sustained virologic response, but also does not seem to substantially worsen [quality of life].” 

Zobair Younossi
Zobair Younossi

Younossi and colleagues administered the EQ-5D questionnaire of quality of life to 722 patients enrolled in the ADVANCE study at baseline and at weeks 4, 12, 24, 36, 48 and 72. Across all treatment arms, quality-of-life scores worsened during the first 12 weeks, but they returned to baseline by week 72.

In multivariate analyses, after adjusting for EQ-5D baseline scores, age, sex, race, advanced liver disease, comorbidities and adverse events, sustained virologic response was associated with improved EQ-5D index scores at week 72.

References:

  • Younossi ZM. #SA1048. Presented at: Digestive Disease Week 2012 Annual Meeting; May 29-22: San Diego.

Disclosures:

  • The study was funded by Vertex Pharmaceuticals.

    See more from Digestive Disease Week